BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Glucose Health, Inc. GLUC
7 fiscal years on record · USD · FY2016 reported
SEC FILINGS ONLY
Revenue · FY2016
$313,229
▲ 7232.1% vs FY2015
EPS · FY16
$-0.15
Dividend / sh · FY16
—
Payout · FY16
—
ROE · FY16
—
Net margin · FY16
-131.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 313,229.00
Revenue, FY2016 · full 7-year series below
Revenue
Net income
The company lost 131 cents on every revenue dollar this year.
Per share
USD -0.15
Diluted EPS, FY2016
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2016
ROE
Operating margin-27.7%
Net margin-131.0%
Return on assets-1690.7%
Returned to shareholders
—
returned in FY2016 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+1018.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2016
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 33,145.00
total assets, end of FY2016
Total assetsUSD 33,145.00
EquityUSD -495,447.00
CashUSD 20,542.00
Current ratio0.06×
Equity funds -1495% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
·
·
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.15
−0.14
−0.99
−4.91
−0.05
−0.02
−0.03
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
Shares out B
0.00
0.00
0.00
0.00
0.01
0.07
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed